Psychedelics Archives - Page 5 of 68

2 minute read

MindMed’s 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued

January 11, 11:43 AM

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024.

MNMD

9 minute read

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

By Lara Goldstein

January 10, 8:56 PM

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has attracted growing attention and investment.

CYBN

2 minute read

Cybin Inc’s Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results

By Lara Goldstein

January 9, 4:36 PM

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers.

CYBN

3 minute read

Tryp Therapeutics Explores Psilocybin’s Potential In New Trials To Treat IBS And Fibromyalgia

By Lara Goldstein

January 8, 5:22 PM

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.

TRYPF

2 minute read

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA’s Stance, The Therapist’s Role & More

By Lara Goldstein

January 8, 3:33 PM

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

OPTHF

3 minute read

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai’s $50M And More

By Lara Goldstein

January 7, 1:36 PM

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

ATAI

2 minute read

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

By Maureen Meehan

January 6, 4:59 PM

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

ATAI

2 minute read

Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment

By Lara Goldstein

January 4, 3:31 PM

Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.

ATAI

3 minute read

Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development

By Lara Goldstein

January 4, 3:17 PM

Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.

ATAI

2 minute read

AMA’s Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here’s What To Expect

By Lara Goldstein

January 3, 6:50 PM

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.

CMPS